Conventional wisdom has been that respiratory syncytial virus (RSV) – a common virus that causes infection in the lungs – comes and goes in children without any long lasting impact.

MedImmune announced today it will present four abstracts at the American Academy of Pediatrics (AAP) 2008 National Conference & Exhibition that add to the company's growing body of research into the prevention of respiratory syncytial virus (RSV), a leading cause of viral respiratory infection among preterm infants.

University of Texas Medical Branch at Galveston researchers have achieved promising results with a potential new weapon against respiratory syncytial virus, the most common cause of infant hospitalization in the United States.

MedImmune announced today that the company presented results from a retrospective chart review that evaluated the use of Synagis® (palivizumab) as a preventive measure against respiratory syncytial virus (RSV) disease in high-risk infants. RSV is a leading cause of viral respiratory infection among preterm infants.

MedImmune, Inc. today announced results from two important studies presented at the 2007 Infectious Diseases Society of America (IDSA) 45th Annual Meeting adding to the body of knowledge about respiratory syncytial virus (RSV). RSV is a viral pathogen that produces annual outbreaks usually between fall and spring.

The most common cause of infant hospitalization in the United States, respiratory syncytial virus, infects virtually all children by age two. Along with the influenza virus, RSV is a major contributor to the approximately two million infant deaths worldwide caused every year by respiratory infections, according to the World Health Organization.